ORBIMED ADVISORS LLC
SEC Form 13F institutional filer · CIK 0001055951
13F-HR · 17 reported holdings · 2026-03-31
OrbiMed Advisors LLC is a healthcare-focused investment manager.
Reported long-US-equity value
$1.03B
Top-10 concentration
88.1%
ORBIMED ADVISORS LLC — $1.03B AUM allocation strategy
ORBIMED ADVISORS LLC files SEC Form 13F and reports $1.03B of long US equity value across 17 reported holdings for 2026-03-31.
Its largest sector bet is Health Care 93.9%, followed by Financials 6.1%.
The top 10 holdings account for 88% of reported value — a conviction-weighted book concentrated in its best ideas. The sector and industry splits below are of the same reported value. Track quarter-over-quarter adds, trims, new positions and exits below — sourced from SEC 13F filings, public domain.
ORBIMED ADVISORS LLC — latest SEC 13F insights
Reported long-US-equity value (13F AUM)
$1.03B
total across 17 reported holdings · 2026-03-31 · excludes shorts, cash, non-US
Top-10 concentration
88% of value
higher = narrower conviction; lower = spread / hedging
Biggest adds (shares)
+$PFE +294K sh · +$13.5M+$BMY +150K sh · +$14.3M+$ELV +15.6K sh · −$1.16M
Biggest trims (shares)
−$EW −612K sh · −$58.6M−$SYK −143K sh · −$54.3M−$LLY −64.4K sh · −$106M
Sector allocation (share of reported value)
each slice is a share of the reported long-US-equity value — smaller sectors and the rest of the book roll into “Other holdings”
Qtr shift = share-point change vs the prior quarter's filing — first period tracked for this filer; the column fills in with the next quarterly refresh.
Industry allocation (share of reported value)
- Pharmaceuticals39.8%—
- Health Care Equipment39.3%—
- Life Sciences Tools & Services7.1%—
- Asset Management & Custody Banks6.1%—
- Biotechnology4.4%—
- Managed Health Care3.3%—
the finer GICS cut of the same book — same denominator — smaller industries roll into “Other holdings”
Qtr shift = share-point change vs the prior quarter's filing — first period tracked for this filer; the column fills in with the next quarterly refresh.
Top S&P 500 holdings
10 of 10 rows · sorted by Value ↓
| Ticker | Holding | Shares | Value | Δ QoQ | Weight |
|---|---|---|---|---|---|
| $LLY | Eli Lilly and Company | 237K | $218M | -64.4K | 21.2% |
| $BSX | Boston Scientific Corporation | 2.38M | $149M | -37.2K | 14.6% |
| $EW | Edwards Lifesciences Corporation | 1.23M | $98.5M | -612K | 9.6% |
| $ISRG | Intuitive Surgical Inc | 209K | $96.2M | -54.7K | 9.4% |
| $MRK | Merck & Company Inc | 663K | $79.8M | — | 7.8% |
| $SYK | Stryker Corporation | 183K | $60M | -143K | 5.8% |
| $BMY | Bristol-Myers Squibb Company | 925K | $56.1M | +150K | 5.5% |
| $PFE | Pfizer Inc | 1.95M | $54.7M | +294K | 5.3% |
| $DHR | Danaher Corporation | 266K | $50.4M | -34K | 4.9% |
| $BNY | The Bank of New York Mellon Corporation | 182K | $41.6M | +10K | 4.1% |
…and 7 more holdings in the full 13F filing (top positions only shown).
SEC Form 13F data sets · public domain · 45-day filing lag · >$100M AUM managers · as reported
← All 13F filers·← QuantOrb.pro
How to read Δ QoQ — the five insight categories, and the caveats
The categories. Analysts, quants and retail traders look past total portfolio value to isolate actionable signals. Five categories matter.
Conviction & concentration shifts
New positions vs complete exits — a brand-new stock signals high conviction; a full liquidation suggests a broken thesis or tax-loss harvesting. Aggressive sizing — look at share count, not dollars: a 20% share increase during a drawdown is strong dip-buying. Concentration — a narrowing top-5/10 means conviction; spreading capital across more names means hedging.
Sector & macro allocation rotations
Aggregating Δ QoQ moves across sectors shows where smart money is leaning in or sneaking out — rotating out of growth into defensives or energy, for example. The fund's total long equity exposure quarter-over-quarter is a proxy for overall institutional risk appetite.
Crowding & smart-money consensus
When several managers initiate or expand the same stock in the same quarter, that is institutional consensus. Contrarian reads: top pickers buying hard into a beaten-down name the market is selling.
Derivative & option overlays
Reported call/put changes indicate whether managers are adding downside hedges or leveraging upside exposure. Note: a long increase may be half of a market-neutral pair trade.
Who reads this
| Retail "cloners" | High-conviction ideas to replicate ~45 days after quarter-end. |
| Corporate IR | Which funds bought or dumped the stock, before the next call. |
| Quant / algo traders | Cross-sectional factor inputs: flow, momentum, ownership. |
Four caveats before you trade on it
- 45-day lag — holdings are quarter-end; positions may already be closed.
- Long-only — 13Fs miss shorts, pair trades and cash.
- No non-US / fixed income — the picture is US equities plus options.
- Corporate actions — splits and spinoffs distort raw share deltas.
Newsletter signup
Free subscription. Daily trading day morning dispatch. No spam.